With its top academic institutions, Boston has long been a Mecca for biotechnology companies. But the demand for more academic input into industrial science is luring top drug companies there too, says Corie Lok.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Author notes
http://beta.network.nature.com/boston
Corie Lok is the editor of Nature Network Boston.
- Corie Lok
Additional information
Related links
Rights and permissions
About this article
Cite this article
Lok, C. Bound for Boston. Nature 441, 780–781 (2006). https://doi.org/10.1038/nj7094-780a
Published:
Issue Date:
DOI: https://doi.org/10.1038/nj7094-780a
This article is cited by
-
Mission possible: managing innovation in drug discovery
Nature Biotechnology (2007)
